Share Twitter LinkedIn Facebook Email Sara M. Tolaney, MD, MPH, the fulvestrant + ribociclib arm of the MONALEESA-3 study
Enhertu DESTINY-Breast06 Phase III Study the Impact on HR-Positive, HER2-Low Metastatic Breast Cancer Revealed Breast 4 Mins Read
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read